All In Biotech

Drug Trial Radar · NCT01425632

A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (A Randomized, Double-blind, Placebo-controlled Study)

Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 490 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

490

Actual

Start

Aug 2011

Primary completion

Dec 2011

Study completion Dec 2011

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Aug 30, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 7 years, up to 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are: to confirm the superiority of TAU-284 over placebo after two weeks of administration to pediatric patients with perennial allergic rhinitis, and to investigate the dose response, safety, and plasma concentrations of TAU-284.

Conditions

  • Perennial Allergic Rhinitis

Interventions

  • TAU-284Drug

    TAU-284 Low

  • TAU-284Drug

    TAU-284 High

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion] (at Final Evaluation)Time frame: Baseline and Week 2

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Reserch site

    Chūbu, Japan

  • Reserch site

    Hokuriku, Japan

  • Reserch site

    Kanto, Japan

  • Reserch site

    Kinki, Japan

  • Reserch site

    Kyusyu, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.